Pinkmartini的个人主页 - 老虎社区

Pinkmartini

Pinkmartini

A solo and freestyle trader

IP属地：未知

169关注

3粉丝

0主题

0勋章

2021-10-20

Heard that this was old news by Politico, causing the dip of the shares.

Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>

2021-07-02

Always read more details and find out the companies that you are buying before you stuck with all these stocks.

抱歉，原内容已删除

2021-07-09

👍 nice

Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>

2021-09-21

😭gloomy day

Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote>

2021-09-14

$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.

2021-07-30

Hoping it will go higher😁

Exxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote>

2021-07-14

$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound

2021-06-26

Yes APPLE is definitely a better buy😉

抱歉，原内容已删除

2021-06-26

It is kinda high now to buy in ~

抱歉，原内容已删除

2021-10-25

👍

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3585729847029660","uuid":"3585729847029660","gmtCreate":1622795342156,"gmtModify":1634652902800,"name":"Pinkmartini","pinyin":"pinkmartini","introduction":"","introductionEn":"","signature":"A solo and freestyle trader","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":169,"tweetSize":31,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.60%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":875712367,"gmtCreate":1637686423087,"gmtModify":1637686423087,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875712367","repostId":"1113618972","repostType":2,"isVote":1,"tweetType":1,"viewCount":2148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844014029,"gmtCreate":1636377122334,"gmtModify":1636377123305,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844014029","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":3619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856801556,"gmtCreate":1635166123276,"gmtModify":1635166123394,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856801556","repostId":"851921142","repostType":1,"repost":{"id":851921142,"gmtCreate":1634865151633,"gmtModify":1635053291354,"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583318222987864","authorIdStr":"3583318222987864"},"themes":[],"htmlText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","listText":"Here’s why the <a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Covid 19 pill WILLNOT make the <a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines&nbsp;in Sep/ Oct 2021.&nbsp;While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Covid 19 vaccine &amp; the company’s&nbsp;stock price went through some wild fluctuations, there was no plunge","text":"Here’s why the $Merck(MRK)$Covid 19 pill WILLNOT make the $Novavax(NVAX)$Covid 19 vaccine irrelevant.Novavax was saved from the brink of bankruptcy by successfully formulating a non-mRNA Covid 19 vaccine with high efficacy. Its stock price was running high for the most part of 2020 - 2021. That was until the news of the Merck Covid 19 pill made headlines in Sep/ Oct 2021. While public confidence in Novavax started to waver months earlier due to the pharmaceutical company’s repeated delays in filing for emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its Covid 19 vaccine & the company’s stock price went through some wild fluctuations, there was no plunge","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851921142","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","kind":"news","pubTimestamp":1632091615,"share":"https://www.laohu8.com/m/news/1194891884?lang=zh_CN&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周重头戏将是美联储9月政策会议。投资者还将关注几家公司的财报发布、投资者日和最新的经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar将于周一公布季度收益，随后Adobe、AutoZone和FedEx将于周二公布业绩。通用磨坊周三上市，然后耐克、埃森哲、好市多批发和达顿餐厅周四上市。本周的投资者日包括周二的Biogen、周三的Weyerhaeuser和周四的Salesforce。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆·鲍威尔的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括周四公布的世界大型企业联合会8月份领先经济指数。美国房地产市场还将发布多项更新，包括周一全国住宅建筑商协会9月份住房市场指数、周二人口普查局8月份新住宅建设数据以及全国房地产经纪人协会现房销售数据。周三八月。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>星期一9/20</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar报告2021财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤内科学会2021年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>房屋建筑商协会发布了9月份的房地产市场指数。经济学家预测为73，比8月份的数据低两个百分点，这是一年多来的最低水平。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>星期二9/21</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone和FedEx发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健(Biogen)举办投资者日活动，讨论其神经科学治疗产品线。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>八月份新住宅建设报告。市场普遍估计，经季节调整后的新屋开工年率为155万套，比7月份的水平高出1%。新屋开工量较今年3月达到的金融危机后172.5万套的峰值有所下降。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9/22星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>FOMC宣布</b>它的货币政策决定。美联储可能会将联邦基金利率维持在接近零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布2022财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股举办2021年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布其货币政策决定。市场普遍预计日本央行将把关键短期利率维持在负0.1%不变，因为由于Covid-19德尔塔变异毒株，东京都和其他地区在9月底之前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份现房销售情况。预计经季节调整后的房屋销售量为578,000套，比7月份的599,000套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>星期四9/23</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>Accenture、Costco Wholesale、Darden Restaurants和Nike在评级召开会议讨论季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com举办2021年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将是参与者之一。Salesforce今年夏天完成了对Slack的280亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>世界大型企业联合会</b>发布8月份领先经济指数。经济学家预测环比增长0.5%，7月份增长0.9%。世界大型企业联合会目前预计2021年国内生产总值增长6%，2022年增长4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>星期五9/24</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方铁路公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-20 06:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周重头戏将是美联储9月政策会议。投资者还将关注几家公司的财报发布、投资者日和最新的经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar将于周一公布季度收益，随后Adobe、AutoZone和FedEx将于周二公布业绩。通用磨坊周三上市，然后耐克、埃森哲、好市多批发和达顿餐厅周四上市。本周的投资者日包括周二的Biogen、周三的Weyerhaeuser和周四的Salesforce。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆·鲍威尔的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括周四公布的世界大型企业联合会8月份领先经济指数。美国房地产市场还将发布多项更新，包括周一全国住宅建筑商协会9月份住房市场指数、周二人口普查局8月份新住宅建设数据以及全国房地产经纪人协会现房销售数据。周三八月。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>星期一9/20</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar报告2021财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤内科学会2021年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>房屋建筑商协会发布了9月份的房地产市场指数。经济学家预测为73，比8月份的数据低两个百分点，这是一年多来的最低水平。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>星期二9/21</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone和FedEx发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健(Biogen)举办投资者日活动，讨论其神经科学治疗产品线。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>八月份新住宅建设报告。市场普遍估计，经季节调整后的新屋开工年率为155万套，比7月份的水平高出1%。新屋开工量较今年3月达到的金融危机后172.5万套的峰值有所下降。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9/22星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>FOMC宣布</b>它的货币政策决定。美联储可能会将联邦基金利率维持在接近零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布2022财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股举办2021年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布其货币政策决定。市场普遍预计日本央行将把关键短期利率维持在负0.1%不变，因为由于Covid-19德尔塔变异毒株，东京都和其他地区在9月底之前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份现房销售情况。预计经季节调整后的房屋销售量为578,000套，比7月份的599,000套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>星期四9/23</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>Accenture、Costco Wholesale、Darden Restaurants和Nike在评级召开会议讨论季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com举办2021年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将是参与者之一。Salesforce今年夏天完成了对Slack的280亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>世界大型企业联合会</b>发布8月份领先经济指数。经济学家预测环比增长0.5%，7月份增长0.9%。世界大型企业联合会目前预计2021年国内生产总值增长6%，2022年增长4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>星期五9/24</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方铁路公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDX":"联邦快递","ADBE":"Adobe",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","COST":"好市多",".DJI":"道琼斯","CRM":"赛富时","NKE":"耐克"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1,"symbols_score_info":{".SPX":0.9,"COST":0.9,".DJI":0.9,".IXIC":0.9,"CRM":0.9,"NKE":0.9,"ADBE":0.9,"FDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895481324,"gmtCreate":1628765708468,"gmtModify":1631888964471,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Impressive 😄","listText":"Impressive 😄","text":"Impressive 😄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/895481324","repostId":"1176507211","repostType":2,"repost":{"id":"1176507211","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628755698,"share":"https://www.laohu8.com/m/news/1176507211?lang=zh_CN&edition=full","pubTime":"2021-08-12 16:08","market":"us","language":"en","title":"Clover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health股价在盘前交易中上涨近12%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176507211","media":"Tiger Newspress","summary":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Hea","content":"<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p><p><blockquote>Clover Health股价在盘前交易中上涨近12%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p><p><blockquote>医疗保健技术公司<b>三叶草健康</b>周三下午公布了第二季度收益。</blockquote></p><p> Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p><p><blockquote>Clover Health第二季度营收4.12亿美元，同比增长140%。该季度总收入超出了分析师预期的2.054亿美元。</blockquote></p><p> Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p><p><blockquote>Clover Health预计整个财年的收入将在14亿至15亿美元之间。该收入指引高于分析师8.115亿美元的预期。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health股价在盘前交易中上涨近12%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health shares rose nearly 12% in premarket trading.<blockquote>Clover Health股价在盘前交易中上涨近12%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-12 16:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Clover Health&nbsp;shares&nbsp;rose nearly&nbsp;12% in premarket&nbsp;trading.</p><p><blockquote>Clover Health股价在盘前交易中上涨近12%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/873c1d06cbd5a2c42b775f8b93fec480\" tg-width=\"910\" tg-height=\"651\" referrerpolicy=\"no-referrer\">Health care technology company&nbsp;<b>Clover Health</b>&nbsp;reported second-quarter earnings Wednesday afternoon.</p><p><blockquote>医疗保健技术公司<b>三叶草健康</b>周三下午公布了第二季度收益。</blockquote></p><p> Clover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.</p><p><blockquote>Clover Health第二季度营收4.12亿美元，同比增长140%。该季度总收入超出了分析师预期的2.054亿美元。</blockquote></p><p> Clover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.</p><p><blockquote>Clover Health预计整个财年的收入将在14亿至15亿美元之间。该收入指引高于分析师8.115亿美元的预期。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176507211","content_text":"Clover Health shares rose nearly 12% in premarket trading.\nHealth care technology company Clover Health reported second-quarter earnings Wednesday afternoon.\nClover Health had revenue of $412 million in the second quarter, up 140% year-over-year. The revenue total beat analysts’ estimate of $205.4 million for the quarter.\nClover Health sees full fiscal year revenue coming in the range of $1.4 billion to $1.5 billion. The revenue guidance is ahead of an $811.5 million estimate from analysts.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":3017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807216642,"gmtCreate":1628038631786,"gmtModify":1631888964486,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/807216642","repostId":"1128701390","repostType":4,"isVote":1,"tweetType":1,"viewCount":2662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohu8.com/m/news/2155158989?lang=zh_CN&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了其第一个季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>去年因COVID-19大流行削减需求而实施的大幅成本削减仍然存在，使得价格上涨能够提振利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度以31.9亿美元的营业利润领先。本季度产量下降2%，至360万油当量桶/日。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为46.9亿美元，即每股1.10美元，而去年同期亏损10.8亿美元，即每股26美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-30 19:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了其第一个季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>去年因COVID-19大流行削减需求而实施的大幅成本削减仍然存在，使得价格上涨能够提振利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度以31.9亿美元的营业利润领先。本季度产量下降2%，至360万油当量桶/日。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为46.9亿美元，即每股1.10美元，而去年同期亏损10.8亿美元，即每股26美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":1740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800206092,"gmtCreate":1627302702016,"gmtModify":1631888964510,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Yea it will go higher&nbsp;","listText":"Yea it will go higher&nbsp;","text":"Yea it will go higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800206092","repostId":"800203376","repostType":1,"repost":{"id":800203376,"gmtCreate":1627302521391,"gmtModify":1627313418331,"author":{"id":"3514329116425907","authorId":"3514329116425907","name":"小虎AV","avatar":"https://static.tigerbbs.com/162e12f8dcec770ec19f66f2abb0d5db","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3514329116425907","authorIdStr":"3514329116425907"},"themes":[],"title":"Apple stock hits record high: can it go higher?","htmlText":"\n \n \n  Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>\n \n","listText":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>","text":"Krish Sankar, senior research analyst at Cowen, joined \"Squawk Box\" to discuss his outperform rating and $180 price target on Apple's stock.$Apple(AAPL)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/800203376","isVote":1,"tweetType":2,"object":{"id":"bfaa109abbbf47f287e65d43086bc18d","tweetId":"800203376","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/cd0c38dc3701925921575081150/GALbAs4cmwYA.mp4","poster":"https://static.tigerbbs.com/10fac7242dd064ef2fda4f5c609ffb73"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178984102,"gmtCreate":1626781934506,"gmtModify":1631884320896,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Hope market rebound soon","listText":"Hope market rebound soon","text":"Hope market rebound soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178984102","repostId":"145269204","repostType":1,"repost":{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":1024,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","kind":"news","pubTimestamp":1625841673,"share":"https://www.laohu8.com/m/news/1113783042?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社）-中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达18亿元人民币（2.778亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是EVE为确保锂等电动汽车电池原料而做出的最新倾斜。此前，该公司持有钴生产商浙江华友钴业的少量股份，以及与华友一起在印度尼西亚投资21亿美元的镍钴项目17%的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE表示，两家公司同意在青海成立一家合资企业，金库伦持股80%，金库伦持股20%，建设一座年产3万吨电池化学品碳酸锂和氢氧化锂的工厂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，第一阶段的产量将为10,000吨，使项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，该合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>根据《亚洲金属》的评估，中国电池级碳酸锂的价格在过去一个月下跌了约2%，但随着需求在经历了三年的低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-09 22:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社）-中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达18亿元人民币（2.778亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是EVE为确保锂等电动汽车电池原料而做出的最新倾斜。此前，该公司持有钴生产商浙江华友钴业的少量股份，以及与华友一起在印度尼西亚投资21亿美元的镍钴项目17%的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE表示，两家公司同意在青海成立一家合资企业，金库伦持股80%，金库伦持股20%，建设一座年产3万吨电池化学品碳酸锂和氢氧化锂的工厂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，第一阶段的产量将为10,000吨，使项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，该合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>根据《亚洲金属》的评估，中国电池级碳酸锂的价格在过去一个月下跌了约2%，但随着需求在经历了三年的低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1,"symbols_score_info":{"300014":0.9}},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140747649,"gmtCreate":1625677882381,"gmtModify":1631888964538,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Finally it soar again after a few months of low&nbsp;","listText":"Finally it soar again after a few months of low&nbsp;","text":"Finally it soar again after a few months of low","images":[{"img":"https://static.tigerbbs.com/2aba790188331bc227004cc234155500","width":"1125","height":"3633"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140747649","isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":140120190,"gmtCreate":1625638951210,"gmtModify":1631888964548,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","listText":"SDNL when is&nbsp;the next surge again? Any &nbsp; &nbsp; Feedback on this stocks&nbsp;","text":"SDNL when is the next surge again? Any Feedback on this stocks","images":[{"img":"https://static.tigerbbs.com/db83977a908c8cdd0e78c34cc5e64da7","width":"1125","height":"3828"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140120190","isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":156603367,"gmtCreate":1625215125259,"gmtModify":1631888964562,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"The future travel","listText":"The future travel","text":"The future travel","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156603367","repostId":"2148666820","repostType":4,"repost":{"id":"2148666820","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625212861,"share":"https://www.laohu8.com/m/news/2148666820?lang=zh_CN&edition=full","pubTime":"2021-07-02 16:01","market":"us","language":"en","title":"Branson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于7月11日先于贝佐斯进行太空旅行</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2148666820","media":"Tiger Newspress","summary":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson wil","content":"<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p><p><blockquote>维珍银河股价在盘前交易中飙升37%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p><p><blockquote>亿万富翁企业家理查德·布兰森将前往太空边缘<a href=\"https://laohu8.com/S/SPCE.WS\">维珍银河控股公司</a>布兰森的太空旅游公司周四表示，布兰森将于7月11日进行试飞，击败了同样有抱负的亿万富翁宇航员杰夫·贝索斯。</blockquote></p><p> A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p><p><blockquote>布兰森乘坐维珍VSS Unity太空飞机的成功飞行将标志着私人商业太空旅行新时代竞赛中的一个重要里程碑。</blockquote></p><p> It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p><p><blockquote>这也意味着布兰森将先于竞争对手太空旅游企业蓝色起源的创始人贝佐斯超越地球大气层。</blockquote></p><p> Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p><p><blockquote>贝佐斯是零售巨头亚马逊公司的创始人，他计划于7月20日与他的兄弟Mark、开创性的女飞行员Wally Funk以及一名迄今为止身份不明的人一起飞往太空，Mark投入了2800万美元加入亚轨道兜风。</blockquote></p><p> Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p><p><blockquote>路透社上个月报道称，就在贝佐斯计划旅行的前几天，布兰森正在考虑执行一项引人注目的任务。</blockquote></p><p> The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p><p><blockquote>SpaceX首席执行官埃隆·马斯克(Elon Musk)也参加了这场竞赛，人们乐观地认为，随着新兴技术得到验证和成本下降，太空旅行将成为主流，瑞银估计，到2030年，每年的旅游市场可能达到30亿美元。马斯克尚未确定太空飞行的日期。</blockquote></p><p> \"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p><p><blockquote>布兰森在维珍公告附带的一份声明中表示：“维珍银河处于新商业航天行业的先锋地位，该行业将向人类开放太空并永远改变世界。”</blockquote></p><p> Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p><p><blockquote>维珍表示，布兰森7月11日的任务将是VSS Unity的第22次飞行测试，也是该公司的第四次载人航天飞行。</blockquote></p><p> But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p><p><blockquote>但它将是第一个搭载由两名飞行员和四名“任务专家”组成的全体机组人员的飞机，其中包括布兰森。</blockquote></p><p> Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p><p><blockquote>维珍表示，在维珍预计2022年开始商业服务之前，计划再进行两次试飞。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于7月11日先于贝佐斯进行太空旅行</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson aims to make space trip on July 11, ahead of Bezos<blockquote>布兰森计划于7月11日先于贝佐斯进行太空旅行</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-02 16:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Virgin Galactic&nbsp;stock&nbsp;surged&nbsp;37%&nbsp;in premarket trading.</p><p><blockquote>维珍银河股价在盘前交易中飙升37%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ec18b866bf2b11226994a81dad0c7a78\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Billionaire entrepreneur Richard Branson will travel to the edge of space on <a href=\"https://laohu8.com/S/SPCE.WS\">Virgin Galactic Holdings Inc</a>'s test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.</p><p><blockquote>亿万富翁企业家理查德·布兰森将前往太空边缘<a href=\"https://laohu8.com/S/SPCE.WS\">维珍银河控股公司</a>布兰森的太空旅游公司周四表示，布兰森将于7月11日进行试飞，击败了同样有抱负的亿万富翁宇航员杰夫·贝索斯。</blockquote></p><p> A successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.</p><p><blockquote>布兰森乘坐维珍VSS Unity太空飞机的成功飞行将标志着私人商业太空旅行新时代竞赛中的一个重要里程碑。</blockquote></p><p> It would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.</p><p><blockquote>这也意味着布兰森将先于竞争对手太空旅游企业蓝色起源的创始人贝佐斯超越地球大气层。</blockquote></p><p> Bezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.</p><p><blockquote>贝佐斯是零售巨头亚马逊公司的创始人，他计划于7月20日与他的兄弟Mark、开创性的女飞行员Wally Funk以及一名迄今为止身份不明的人一起飞往太空，Mark投入了2800万美元加入亚轨道兜风。</blockquote></p><p> Reuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.</p><p><blockquote>路透社上个月报道称，就在贝佐斯计划旅行的前几天，布兰森正在考虑执行一项引人注目的任务。</blockquote></p><p> The race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.</p><p><blockquote>SpaceX首席执行官埃隆·马斯克(Elon Musk)也参加了这场竞赛，人们乐观地认为，随着新兴技术得到验证和成本下降，太空旅行将成为主流，瑞银估计，到2030年，每年的旅游市场可能达到30亿美元。马斯克尚未确定太空飞行的日期。</blockquote></p><p> \"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.</p><p><blockquote>布兰森在维珍公告附带的一份声明中表示：“维珍银河处于新商业航天行业的先锋地位，该行业将向人类开放太空并永远改变世界。”</blockquote></p><p> Branson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.</p><p><blockquote>维珍表示，布兰森7月11日的任务将是VSS Unity的第22次飞行测试，也是该公司的第四次载人航天飞行。</blockquote></p><p> But it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.</p><p><blockquote>但它将是第一个搭载由两名飞行员和四名“任务专家”组成的全体机组人员的飞机，其中包括布兰森。</blockquote></p><p> Two additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.</p><p><blockquote>维珍表示，在维珍预计2022年开始商业服务之前，计划再进行两次试飞。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AMZN":"亚马逊","03086":"华夏纳指","SPCE":"维珍银河","QNETCN":"纳斯达克中美互联网老虎指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148666820","content_text":"Virgin Galactic stock surged 37% in premarket trading.\n\nBillionaire entrepreneur Richard Branson will travel to the edge of space on Virgin Galactic Holdings Inc's test flight on July 11, Branson's space tourism firm said on Thursday, beating out fellow aspiring billionaire astronaut Jeff Bezos.\nA successful flight by Branson aboard Virgin's VSS Unity spaceplane would mark a key milestone in a race to usher in a new era of private commercial space travel.\nIt would also mean that Branson would travel beyond Earth's atmosphere ahead of Bezos, the founder of rival space tourism venture Blue Origin.\nBezos, who founded retail giant Amazon.com Inc, is slated to fly to space on July 20 along with his brother, Mark, trailblazing female pilot Wally Funk and a so-far unidentified person who plunked down $28 million to join the suborbital joyride.\nReuters reported last month that Branson was considering a show-stealing mission just days ahead of Bezos' planned trip.\nThe race, which also includes SpaceX Chief Executive Elon Musk, is underpinned by optimism that space travel will become mainstream as nascent technology is proven and costs fall, fueling what UBS estimates could be a $3 billion annual tourism market by 2030. Musk has not set a date for his space flight.\n\"Virgin Galactic stands at the vanguard of a new commercial space industry, which is set to open space to humankind and change the world for good,\" Branson said in a statement accompanying Virgin's announcement.\nBranson's July 11 mission will be the twenty-second flight test for VSS Unity, and the company's fourth crewed spaceflight, Virgin said.\nBut it will be the first to carry a full crew of two pilots and four \"mission specialists,\" including Branson.\nTwo additional test flights are planned before Virgin expects to begin commercial service in 2022, Virgin said.","news_type":1,"symbols_score_info":{"09086":0.9,"AMZN":0.9,"03086":0.9,"QNETCN":0.9,"SPCE":0.9}},"isVote":1,"tweetType":1,"viewCount":673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151095720,"gmtCreate":1625056254660,"gmtModify":1631888964586,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Way to go","listText":"Way to go","text":"Way to go","images":[{"img":"https://static.tigerbbs.com/58f1cebd190596fc00c4e1e79a1da49d","width":"1125","height":"3558"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151095720","isVote":1,"tweetType":1,"viewCount":852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153084347,"gmtCreate":1624986192089,"gmtModify":1631891361228,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","listText":"I don’t think it would crash. Depending which angle you are looking at .&nbsp;","text":"I don’t think it would crash. Depending which angle you are looking at .","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153084347","repostId":"2146388793","repostType":4,"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":859408655,"gmtCreate":1634718204697,"gmtModify":1634718404868,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","listText":"Heard that this was&nbsp;old news by Politico, causing the dip of the shares.&nbsp;","text":"Heard that this was old news by Politico, causing the dip of the shares.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859408655","repostId":"1174375951","repostType":4,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":156001375,"gmtCreate":1625184494997,"gmtModify":1631888964579,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","listText":"Always read more details&nbsp;and find out the companies that you are buying before you stuck with all these stocks.&nbsp;","text":"Always read more details and find out the companies that you are buying before you stuck with all these stocks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/156001375","repostId":"2148682246","repostType":4,"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141185907,"gmtCreate":1625842118809,"gmtModify":1631888964523,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"👍 nice","listText":"👍 nice","text":"👍 nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/141185907","repostId":"1113783042","repostType":4,"repost":{"id":"1113783042","kind":"news","pubTimestamp":1625841673,"share":"https://www.laohu8.com/m/news/1113783042?lang=zh_CN&edition=full","pubTime":"2021-07-09 22:41","market":"sh","language":"en","title":"Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113783042","media":"Reuters","summary":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium","content":"<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社）-中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达18亿元人民币（2.778亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是EVE为确保锂等电动汽车电池原料而做出的最新倾斜。此前，该公司持有钴生产商浙江华友钴业的少量股份，以及与华友一起在印度尼西亚投资21亿美元的镍钴项目17%的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE表示，两家公司同意在青海成立一家合资企业，金库伦持股80%，金库伦持股20%，建设一座年产3万吨电池化学品碳酸锂和氢氧化锂的工厂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，第一阶段的产量将为10,000吨，使项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，该合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>根据《亚洲金属》的评估，中国电池级碳酸锂的价格在过去一个月下跌了约2%，但随着需求在经历了三年的低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese battery maker EVE to invest in lithium production<blockquote>中国电池制造商EVE将投资锂生产</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-09 22:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).</p><p><blockquote>（路透社）-中国电池制造商亿纬锂能周五表示，将入股一家小型锂生产商，并成立一家合资企业，建设一个耗资高达18亿元人民币（2.778亿美元）的锂化学品项目。</blockquote></p><p> The move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.</p><p><blockquote>此举是EVE为确保锂等电动汽车电池原料而做出的最新倾斜。此前，该公司持有钴生产商浙江华友钴业的少量股份，以及与华友一起在印度尼西亚投资21亿美元的镍钴项目17%的权益。</blockquote></p><p> EVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.</p><p><blockquote>总部位于中国南方惠州的EVE在一份交易所文件中表示，计划收购金库伦锂业有限公司28.1%的股权，该公司在中国西北部以锂盐湖闻名的青海省生产金属锂。</blockquote></p><p> The two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.</p><p><blockquote>EVE表示，两家公司同意在青海成立一家合资企业，金库伦持股80%，金库伦持股20%，建设一座年产3万吨电池化学品碳酸锂和氢氧化锂的工厂。</blockquote></p><p> First-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.</p><p><blockquote>它补充说，第一阶段的产量将为10,000吨，使项目总建设时间不超过36个月。</blockquote></p><p> EVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.</p><p><blockquote>EVE表示，该合资企业“有利于提高公司供应链的稳定性”，可以减少原材料价格波动的不利影响。</blockquote></p><p> Prices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.</p><p><blockquote>根据《亚洲金属》的评估，中国电池级碳酸锂的价格在过去一个月下跌了约2%，但随着需求在经历了三年的低迷后反弹，2021年迄今为止仍上涨了65%以上。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"300014":"亿纬锂能"},"source_url":"https://finance.yahoo.com/news/chinese-battery-maker-eve-invest-141811727.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113783042","content_text":"(Reuters) - Chinese battery maker EVE Energy said on Friday it would take a stake in a small lithium producer and establish a joint venture to build a lithium chemicals project costing up to 1.8 billion yuan ($277.8 million).\nThe move is EVE's latest tilt to secure ingredients for batteries used in electric vehicles, such as lithium. It previously took a small stake in cobalt producer Zhejiang Huayou Cobalt and a 17% interest in a $2.1 billion nickel and cobalt project alongside Huayou in Indonesia.\nEVE, based in Huizhou in southern China, said in an exchange filing it planned to take 28.1% equity in Jinkulun Lithium Industry Co, which makes lithium metal in China's northwestern Qinghai province, known for its lithium salt lakes.\nThe two companies agreed to set up a Qinghai-based venture 80% owned by and 20% owned by Jinkulun to build a plant to make 30,000 tonnes per year of battery chemicals lithium carbonate and lithium hydroxide, EVE said.\nFirst-phase output would be 10,000 tonnes, it added, putting the total project construction time at no more than 36 months.\nEVE said the venture was \"conducive to improving the stability of the company's supply chains\" and could reduce the adverse impact of raw material price fluctuations.\nPrices for battery-grade lithium carbonate in China, as assessed by Asian Metal, have fallen about 2% in the past month but are still up more than 65% so far in 2021 as demand roars back after a three-year downturn.","news_type":1,"symbols_score_info":{"300014":0.9}},"isVote":1,"tweetType":1,"viewCount":725,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860844688,"gmtCreate":1632156617744,"gmtModify":1632802435367,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"😭gloomy day","listText":"😭gloomy day","text":"😭gloomy day","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860844688","repostId":"1194891884","repostType":4,"repost":{"id":"1194891884","kind":"news","pubTimestamp":1632091615,"share":"https://www.laohu8.com/m/news/1194891884?lang=zh_CN&edition=full","pubTime":"2021-09-20 06:46","market":"us","language":"en","title":"Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194891884","media":"Barrons","summary":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also","content":"<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周重头戏将是美联储9月政策会议。投资者还将关注几家公司的财报发布、投资者日和最新的经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar将于周一公布季度收益，随后Adobe、AutoZone和FedEx将于周二公布业绩。通用磨坊周三上市，然后耐克、埃森哲、好市多批发和达顿餐厅周四上市。本周的投资者日包括周二的Biogen、周三的Weyerhaeuser和周四的Salesforce。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆·鲍威尔的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括周四公布的世界大型企业联合会8月份领先经济指数。美国房地产市场还将发布多项更新，包括周一全国住宅建筑商协会9月份住房市场指数、周二人口普查局8月份新住宅建设数据以及全国房地产经纪人协会现房销售数据。周三八月。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>星期一9/20</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar报告2021财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤内科学会2021年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>房屋建筑商协会发布了9月份的房地产市场指数。经济学家预测为73，比8月份的数据低两个百分点，这是一年多来的最低水平。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>星期二9/21</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone和FedEx发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健(Biogen)举办投资者日活动，讨论其神经科学治疗产品线。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>八月份新住宅建设报告。市场普遍估计，经季节调整后的新屋开工年率为155万套，比7月份的水平高出1%。新屋开工量较今年3月达到的金融危机后172.5万套的峰值有所下降。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9/22星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>FOMC宣布</b>它的货币政策决定。美联储可能会将联邦基金利率维持在接近零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布2022财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股举办2021年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布其货币政策决定。市场普遍预计日本央行将把关键短期利率维持在负0.1%不变，因为由于Covid-19德尔塔变异毒株，东京都和其他地区在9月底之前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份现房销售情况。预计经季节调整后的房屋销售量为578,000套，比7月份的599,000套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>星期四9/23</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>Accenture、Costco Wholesale、Darden Restaurants和Nike在评级召开会议讨论季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com举办2021年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将是参与者之一。Salesforce今年夏天完成了对Slack的280亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>世界大型企业联合会</b>发布8月份领先经济指数。经济学家预测环比增长0.5%，7月份增长0.9%。世界大型企业联合会目前预计2021年国内生产总值增长6%，2022年增长4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>星期五9/24</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方铁路公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNike, Costco, FedEx, Salesforce, and Other Stocks for Investors to Watch This Week<blockquote>耐克、好市多、联邦快递、Salesforce和其他本周值得投资者关注的股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-09-20 06:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.</p><p><blockquote>本周重头戏将是美联储9月政策会议。投资者还将关注几家公司的财报发布、投资者日和最新的经济数据。</blockquote></p><p> Lennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report&nbsp;on Thursday. Investor days this week include&nbsp;Biogen on Tuesday,&nbsp;Weyerhaeuser on Wednesday, and&nbsp;Salesforce.com on Thursday.</p><p><blockquote>Lennar将于周一公布季度收益，随后Adobe、AutoZone和FedEx将于周二公布业绩。通用磨坊周三上市，然后耐克、埃森哲、好市多批发和达顿餐厅周四上市。本周的投资者日包括周二的Biogen、周三的Weyerhaeuser和周四的Salesforce。</blockquote></p><p> The Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely&nbsp;to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s&nbsp;press conference with Fed chair Jerome Powell will be closely&nbsp;watched.</p><p><blockquote>美联储货币政策委员会将于本周周二和周三召开会议。央行不太可能改变其目标利率区间，但可能会更新其开始减少每月资产购买的计划。周三下午美联储主席杰罗姆·鲍威尔的新闻发布会将受到密切关注。</blockquote></p><p> Economic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’&nbsp;existing-home sales for August on Wednesday.</p><p><blockquote>本周公布的经济数据包括周四公布的世界大型企业联合会8月份领先经济指数。美国房地产市场还将发布多项更新，包括周一全国住宅建筑商协会9月份住房市场指数、周二人口普查局8月份新住宅建设数据以及全国房地产经纪人协会现房销售数据。周三八月。</blockquote></p><p> <b>Monday 9/20</b></p><p><blockquote><b>星期一9/20</b></blockquote></p><p> Lennar reports third-quarter fiscal-2021 results.</p><p><blockquote>Lennar报告2021财年第三季度业绩。</blockquote></p><p> Merck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.</p><p><blockquote>默克公司在欧洲肿瘤内科学会2021年大会上展示了其癌症药物组合的数据。</blockquote></p><p> <b>The National Association</b>&nbsp;of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.</p><p><blockquote><b>全国协会</b>房屋建筑商协会发布了9月份的房地产市场指数。经济学家预测为73，比8月份的数据低两个百分点，这是一年多来的最低水平。</blockquote></p><p> <b>Tuesday 9/21</b></p><p><blockquote><b>星期二9/21</b></blockquote></p><p> Adobe, AutoZone, and FedEx release earnings.</p><p><blockquote>Adobe、AutoZone和FedEx发布财报。</blockquote></p><p> Biogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.</p><p><blockquote>百健(Biogen)举办投资者日活动，讨论其神经科学治疗产品线。</blockquote></p><p> <b>The Census Bureau</b>&nbsp;reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.</p><p><blockquote><b>人口普查局</b>八月份新住宅建设报告。市场普遍估计，经季节调整后的新屋开工年率为155万套，比7月份的水平高出1%。新屋开工量较今年3月达到的金融危机后172.5万套的峰值有所下降。</blockquote></p><p> <b>Wednesday 9/22</b></p><p><blockquote><b>9/22星期三</b></blockquote></p><p> <b>The FOMC announces</b>&nbsp;its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.</p><p><blockquote><b>FOMC宣布</b>它的货币政策决定。美联储可能会将联邦基金利率维持在接近零的水平不变，但可能会暗示将在今年晚些时候削减资产购买。</blockquote></p><p> General Mills reports first-quarter fiscal-2022 results.</p><p><blockquote>通用磨坊公布2022财年第一季度业绩。</blockquote></p><p> Boston Scientific,Weyerhaeuser, and&nbsp;Yum China Holdings&nbsp;host their 2021 investor days.</p><p><blockquote>波士顿科学、惠好和百胜中国控股举办2021年投资者日。</blockquote></p><p> <b>TheBank of Japan</b>&nbsp;announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.</p><p><blockquote><b>日本银行</b>宣布其货币政策决定。市场普遍预计日本央行将把关键短期利率维持在负0.1%不变，因为由于Covid-19德尔塔变异毒株，东京都和其他地区在9月底之前仍处于紧急状态。</blockquote></p><p> <b>The National Association</b>&nbsp;of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5%&nbsp;from July’s 599,000.</p><p><blockquote><b>全国协会</b>房地产经纪人报告8月份现房销售情况。预计经季节调整后的房屋销售量为578,000套，比7月份的599,000套下降3.5%。</blockquote></p><p> <b>Thursday 9/23</b></p><p><blockquote><b>星期四9/23</b></blockquote></p><p> Accenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.</p><p><blockquote>Accenture、Costco Wholesale、Darden Restaurants和Nike在评级召开会议讨论季度业绩。</blockquote></p><p> Salesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.</p><p><blockquote>Salesforce.com举办2021年投资者日。首席执行官马克·贝尼奥夫和Slack首席执行官斯图尔特·巴特菲尔德将是参与者之一。Salesforce今年夏天完成了对Slack的280亿美元收购。</blockquote></p><p> <b>The Conference Board</b>&nbsp;releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.</p><p><blockquote><b>世界大型企业联合会</b>发布8月份领先经济指数。经济学家预测环比增长0.5%，7月份增长0.9%。世界大型企业联合会目前预计2021年国内生产总值增长6%，2022年增长4%。</blockquote></p><p> <b>Friday 9/24</b></p><p><blockquote><b>星期五9/24</b></blockquote></p><p> Kansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.</p><p><blockquote>堪萨斯城南方铁路公司召开特别股东大会，就与加拿大太平洋铁路公司的合并提案进行投票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDX":"联邦快递","ADBE":"Adobe",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","COST":"好市多",".DJI":"道琼斯","CRM":"赛富时","NKE":"耐克"},"source_url":"https://www.barrons.com/articles/nike-costco-fedex-salesforce-and-other-stocks-for-investors-to-watch-this-week-51632078208?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194891884","content_text":"The main event this week will be the Federal Reserve’s September policy meeting. Investors will also be watching for several corporate earnings releases, investor days, and the latest economic data.\nLennar reports quarterly earnings on Monday, followed by results from Adobe, AutoZone, and FedEx on Tuesday. General Mills goes on Wednesday, then Nike, Accenture, Costco Wholesale, and Darden Restaurants report on Thursday. Investor days this week include Biogen on Tuesday, Weyerhaeuser on Wednesday, and Salesforce.com on Thursday.\nThe Federal Reserve’s monetary policy committee meets on Tuesday and Wednesday this week. The central bank is unlikely to change its target interest rate range, but could give an update on its plans to begin reducing its monthly asset purchases. Wednesday afternoon’s press conference with Fed chair Jerome Powell will be closely watched.\nEconomic data out this week include the Conference Board’s Leading Economic Index for August on Thursday. There will also be several updates on the U.S. housing market including the National Association of Home Builders’ Housing Market Index for September on Monday, the Census Bureau’s new residential construction data for August on Tuesday, and the National Association of Realtors’ existing-home sales for August on Wednesday.\nMonday 9/20\nLennar reports third-quarter fiscal-2021 results.\nMerck presents data on its portfolio of cancer drugs, in conjunction with the European Society for Medical Oncology’s 2021 Congress.\nThe National Association of Home Builders releases its Housing Market Index for September. Economists forecast a 73 reading, two points below August’s figure, which was the lowest in more than a year.\nTuesday 9/21\nAdobe, AutoZone, and FedEx release earnings.\nBiogen hosts an investor day to discuss its pipeline of neuroscience therapeutics.\nThe Census Bureau reports on new residential construction for August. Consensus estimate is for a seasonally adjusted annual rate of 1.55 million housing starts, 1% higher than the July level. Housing starts are down from their post–financial crisis peak of 1.725 million, reached in March of this year.\nWednesday 9/22\nThe FOMC announces its monetary-policy decision. The Federal Reserve is likely to keep the federal-funds rate unchanged at near zero, but might signal that it will pare its asset purchases later this year.\nGeneral Mills reports first-quarter fiscal-2022 results.\nBoston Scientific,Weyerhaeuser, and Yum China Holdings host their 2021 investor days.\nTheBank of Japan announces its monetary-policy decision. The BOJ is widely expected to keep its key short-term interest rate unchanged at minus 0.1%, as Tokyo and other regions remain in a state of emergency through the end of September due to the Covid-19 Delta variant.\nThe National Association of Realtors reports existing-home sales for August. Expectations are for a seasonally adjusted annual rate of 578,000 homes sold, down 3.5% from July’s 599,000.\nThursday 9/23\nAccenture, Costco Wholesale, Darden Restaurants, and Nike hold conference calls to discuss their quarterly results.\nSalesforce.com holds its 2021 investor day. CEO Marc Benioff and Slack CEO Stewart Butterfield will be among the participants. Salesforce completed its $28 billion acquisition of Slack this summer.\nThe Conference Board releases its Leading Economic Index for August. Economists forecast a 0.5% month-over-month rise, after a 0.9% increase in July. The Conference Board currently projects 6% gross-domestic-product growth for 2021, and 4% for 2022.\nFriday 9/24\nKansas City Southernhosts a special shareholder meeting to vote on a proposed merger withCanadian Pacific Railway.","news_type":1,"symbols_score_info":{".SPX":0.9,"COST":0.9,".DJI":0.9,".IXIC":0.9,"CRM":0.9,"NKE":0.9,"ADBE":0.9,"FDX":0.9}},"isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886401996,"gmtCreate":1631611320315,"gmtModify":1631884988513,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Whether you like it or not,Covid19&nbsp;is here to stay,vaccine is not a cure but&nbsp;to mitigate the risk of death.&nbsp;","text":"$Novavax(NVAX)$Whether you like it or not,Covid19 is here to stay,vaccine is not a cure but to mitigate the risk of death.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/886401996","isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806890941,"gmtCreate":1627646458283,"gmtModify":1631888964499,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Hoping it will go higher😁","listText":"Hoping it will go higher😁","text":"Hoping it will go higher😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806890941","repostId":"2155158989","repostType":2,"repost":{"id":"2155158989","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627644972,"share":"https://www.laohu8.com/m/news/2155158989?lang=zh_CN&edition=full","pubTime":"2021-07-30 19:36","market":"us","language":"en","title":"Exxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2155158989","media":"Tiger Newspress","summary":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its ","content":"<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了其第一个季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>去年因COVID-19大流行削减需求而实施的大幅成本削减仍然存在，使得价格上涨能够提振利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度以31.9亿美元的营业利润领先。本季度产量下降2%，至360万油当量桶/日。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为46.9亿美元，即每股1.10美元，而去年同期亏损10.8亿美元，即每股26美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon posts highest profit in more than a year<blockquote>埃克森美孚创下一年多来最高利润</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-07-30 19:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.</p><p><blockquote>埃克森美孚周五公布了其第一个季度业绩，此前董事会就其方向展开了一场有争议的斗争，由于石油、天然气和化学品需求反弹，埃克森美孚实现了一年多来的最大利润。</blockquote></p><p> Exxon Mobil&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;1%&nbsp;in premarket trading.</p><p><blockquote>埃克森美孚股价在盘前交易中上涨近1%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/004e693406737467f5968e2ae3e8fb09\" tg-width=\"880\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.</p><p><blockquote>石油生产商正在利用上季度原油价格翻倍的机会削减债务并增加股东派息，而不是增加支出来提高产量。</blockquote></p><p> Deep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.</p><p><blockquote>去年因COVID-19大流行削减需求而实施的大幅成本削减仍然存在，使得价格上涨能够提振利润。</blockquote></p><p> Oil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.</p><p><blockquote>石油和天然气生产在本季度以31.9亿美元的营业利润领先。本季度产量下降2%，至360万油当量桶/日。</blockquote></p><p> The company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.</p><p><blockquote>该公司第二季度净利润为46.9亿美元，即每股1.10美元，而去年同期亏损10.8亿美元，即每股26美分，其中包括与扭转库存减记相关的收益。如果没有库存变化，损失将达到30亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155158989","content_text":"Exxon Mobil on Friday posted its first quarterly results following a contested board fight over its direction, registering its biggest profit in more than a year on rebounding demand for oil, gas and chemicals.\nExxon Mobil shares rose nearly 1% in premarket trading.\n\nOil producers are taking advantage of a doubling of crude oil prices last quarter to pare debt and increase shareholder payouts rather than spending more to boost production.\nDeep cost cuts undertaken last year as the COVID-19 pandemic slashed demand have remained, allowing price gains to bolster profits.\nOil and gas production led the way in the quarter with an operating profit of $3.19 billion. Output fell 2% to 3.6 million oil-equivalent barrels per day during the quarter.\nThe company's net income for the second quarter came in at $4.69 billion, or $1.10 per share, compared with a loss of $1.08 billion, or 26 cents per share, a year ago, which included a gain related to reversing an inventory writedown. Absent the inventory change, the loss would have been $3 billion.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":1740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145269204,"gmtCreate":1626225863108,"gmtModify":1631885218880,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","listText":"<a href=\"https://laohu8.com/S/RBLX\">$Roblox Corporation(RBLX)$</a>One of my favourite counter Roblox …. Waiting to rebound","text":"$Roblox Corporation(RBLX)$One of my favourite counter Roblox …. Waiting to rebound","images":[{"img":"https://static.tigerbbs.com/348777b05f0b9f48562e326dd94278ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/145269204","isVote":1,"tweetType":1,"viewCount":1024,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":125760127,"gmtCreate":1624694613169,"gmtModify":1631891361256,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"Yes APPLE is definitely a better buy😉","listText":"Yes APPLE is definitely a better buy😉","text":"Yes APPLE is definitely a better buy😉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125760127","repostId":"1108941456","repostType":4,"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125222641,"gmtCreate":1624676342883,"gmtModify":1631893057831,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"It is kinda&nbsp;high now to buy in ~","listText":"It is kinda&nbsp;high now to buy in ~","text":"It is kinda high now to buy in ~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/125222641","repostId":"1100072036","repostType":4,"isVote":1,"tweetType":1,"viewCount":437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":856808141,"gmtCreate":1635166163293,"gmtModify":1635166163416,"author":{"id":"3585729847029660","authorId":"3585729847029660","name":"Pinkmartini","avatar":"https://static.tigerbbs.com/25f5b3287ef2fcae826d428294e908e8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585729847029660","authorIdStr":"3585729847029660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856808141","repostId":"1137044759","repostType":4,"isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}